Supplementary material for:

Impact of Baseline Hot Flashes on Sleep Metrics During Initial Treatment in LIBERTAS Clinical Trial

Arun Azad[1], Marco Antonio Badillo Santoyo[2], Alicia K Morgans[3], Dana E Rathkopf[4], Karie Runcie[5], Geoffrey Gotto[6], Axel S Merseburger[7], Alex Dos Santos[8], Sukie Shopeju[8], Meenakshi Chatterjee[9], Rana Zia Ur Rehman[10], Daniel Sanchez[8], Bhavini Patel[10], Amitabha Bhaumik[11], Simon Todd[12], Yanran Huo[9], Mark Wildgust[8], Neeraj Agarwal[13]

[1]Peter MacCallum Cancer Centre, Melbourne, Australia; [2]Hospital Aranda de la Parra, Guanajuato, México; [3]Dana-Farber Cancer Institute, Boston, MA, USA; [4]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [5]New York-Presbyterian/Columbia University Medical Center, New York, NY, USA; [6]University of Calgary, Calgary, AB, Canada; [7]University Hospital Schleswig-Holstein, Lübeck, Germany; [8]Johnson & Johnson, Raritan, NJ, USA; [9]Johnson & Johnson, Cambridge, MA, USA; [10]Johnson & Johnson, High Wycombe, UK; [11]Johnson & Johnson, Titusville, NJ, USA; [12]Johnson & Johnson, London, UK; [13]University of Utah Health Hospitals and Clinics, Salt Lake City, UT, USA

Presented by A Azad at ASCO GU; Feb 26, 2026; San Francisco, CA, USA

Supplementary Figure 1: A) Depression severity and B) PGI-C in all enrolled participants

Depression severity scores are based on PHQ-9. PGI-C, Patient Global Impression of Change.

https://www.congresshub.com/Oncology/GU2026/Apalutamide/Azad